Pherecydes Pharma: Commercial Court Rejects Akkadian's Reque

Pherecydes Pharma: Commercial Court Rejects Akkadian's Request to Postpone the Merger Vote: Pherecydes and Erytech Shareholders Will Be Able to Vote on the Merger on June 23, 2023

Regulatory News: Pherecydes Pharma (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announced today

Related Keywords

France , French , Dusan Oresansky Nicolas Fossiez , Arthur Rouill , Erytech Pharma , Pherecydes Pharma , Lyon Commercial Court , Akkadian Pherecydes Pharma , Regulatory News , Lyon Commercial , Akkadian Partner , Oresansky Nicolas Fossiez , Pherecydes , Dharma , Commercial , Court , Rejects , Akkadian , Request , Ostpone , Berger , Vote , Erytech , Shareholders , Hill , Bible , Pune , 023 ,